Literature DB >> 10225968

Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A.

Y Kawaguchi1, M Hara, T M Wright.   

Abstract

It is reported that fibroblasts derived from clinically affected skin areas of patients with systemic sclerosis (SSc) have the ability to overproduce several cytokines and growth factors (i.e., IL-6, PDGF), an ability that might be involved in the pathogenesis of SSc. We have previously shown that the expression of IL-1alpha was constitutively observed in SSc fibroblasts, whereas this was not detected in normal fibroblasts. Although it was suggested that the aberrant IL-1alpha production could be associated with the fibrogenic phenotype of SSc fibroblasts, little is known about the roles of IL-1alpha in SSc fibroblasts. IL-1alpha induced IL-6 and PDGF-A, which are potent stimulators of collagen production and proliferation in normal fibroblasts. This article examines the proposal that IL-6 and PDGF-A are elevated through the action of endogenous IL-1alpha in SSc fibroblasts. An antisense oligodeoxynucleotide complementary to IL-1alpha mRNA was used to suppress endogenous IL-1alpha. Inhibition of endogenous IL-1alpha led to decreased levels of IL-6 and PDGF-A expression in SSc fibroblasts. Moreover, the blocking of the IL-6 response using anti-IL-6 antibody resulted in a significant reduction of procollagen type I in cultured SSc fibroblasts. These results suggest that endogenous IL-1alpha expressed by SSc fibroblasts may play a key role in the abnormal function of SSc fibroblasts through the expression of IL-6 and PDGF-A.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225968      PMCID: PMC408350          DOI: 10.1172/JCI4304

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism.

Authors:  C Boiziau; R Kurfurst; C Cazenave; V Roig; N T Thuong; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

2.  Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts.

Authors:  M Trojanowska; L T Wu; E C LeRoy
Journal:  Oncogene       Date:  1988-10       Impact factor: 9.867

3.  IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA.

Authors:  J A Elias; V Lentz
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

Review 4.  Modulation of eukaryotic gene expression by complementary RNA or DNA sequences.

Authors:  A R van der Krol; J N Mol; A R Stuitje
Journal:  Biotechniques       Date:  1988 Nov-Dec       Impact factor: 1.993

5.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast.

Authors:  E C LeRoy
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

6.  Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer.

Authors:  J A Maier; P Voulalas; D Roeder; T Maciag
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

7.  Regulation of levels of IL-1 mRNA in human fibroblasts.

Authors:  K Yamato; Z el-Hajjaoui; H P Koeffler
Journal:  J Cell Physiol       Date:  1989-06       Impact factor: 6.384

8.  IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts.

Authors:  J M Schröder; M Sticherling; H H Henneicke; W C Preissner; E Christophers
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

9.  Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis.

Authors:  M Kulozik; A Hogg; B Lankat-Buttgereit; T Krieg
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

10.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.

Authors:  R M Burch; L C Mahan
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more
  39 in total

1.  Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Authors:  Pei-Suen Tsou; Nadine N Talia; Adam J Pinney; Ann Kendzicky; Sonsoles Piera-Velazquez; Sergio A Jimenez; James R Seibold; Kristine Phillips; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2011-12-12

2.  The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription.

Authors:  Ariel Werman; Rachel Werman-Venkert; Rosalyn White; Jae-Kwon Lee; Batsheva Werman; Yakov Krelin; Elena Voronov; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 3.  Interleukin 1α and the inflammatory process.

Authors:  Nelson C Di Paolo; Dmitry M Shayakhmetov
Journal:  Nat Immunol       Date:  2016-07-19       Impact factor: 25.606

4.  Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts.

Authors:  Yasushi Kawaguchi; Emi Nishimagi; Akiko Tochimoto; Manabu Kawamoto; Yasuhiro Katsumata; Makoto Soejima; Tokiko Kanno; Naoyuki Kamatani; Masako Hara
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

Review 5.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

6.  Association of interleukin 1 family with systemic sclerosis.

Authors:  Li Zhang; Jun-Wei Yan; Yu-Jie Wang; Ya-Nan Wan; Bing-Xiang Wang; Jin-Hui Tao; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

7.  Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis.

Authors:  Ana Zekovic; Misa Vreca; Vesna Spasovski; Marina Andjelkovic; Sonja Pavlovic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2018-06-08       Impact factor: 2.980

8.  Tocilizumab for the treatment of steroid refractory graft-versus-host disease.

Authors:  William R Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; J Douglas Rizzo; Ayman Saad; Wael Saber; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

9.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Authors:  Yoshihito Shima; Yusuke Kuwahara; Hiroyuki Murota; Shun Kitaba; Mari Kawai; Toru Hirano; Junsuke Arimitsu; Masashi Narazaki; Keisuke Hagihara; Atsushi Ogata; Ichiro Katayama; Ichiro Kawase; Tadamitsu Kishimoto; Toshio Tanaka
Journal:  Rheumatology (Oxford)       Date:  2010-09-05       Impact factor: 7.580

10.  A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression.

Authors:  Bo Hu; Shuhui Wang; Yingze Zhang; Carol A Feghali; Jeffrey R Dingman; Timothy M Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.